Long-Term Impact of RLEs and Final Thoughts

Dr. El-Haddad identifies transparency as the most important long-term impact of establishing RLE terminology and expanding the 505(b)(2) pathway. As more radioligand therapies enter clinical practice through different regulatory routes, clinicians need a clear and consistent way to communicate with one another about the nature of the products they are using and the evidence supporting them. RLE terminology preserves existing FDA regulatory definitions while creating a practical clinical lexicon that improves multidisciplinary communication, supports informed treatment selection, and promotes confidence in clinical decision-making. The ultimate goals are not regulatory reclassification but rather improved communication, expanded patient access, strengthened supply chain resilience, and better patient care.

Closing thoughts from each panelist: Dr. Hendifar reflects on the field's maturation and the novel challenges and opportunities the 505(b)(2) pathway and RLE terminology represent, expressing enthusiasm for the developing landscape. Dr. Soares emphasizes that standardizing this terminology and deepening understanding of the 505(b)(2) pathway across all disciplines involved in NET care will improve access to critical radioligand therapies for patients as the ultimate measure of success. Dr. El-Haddad's take-home message is that 505(b)(2) is a legitimate, rigorous FDA approval pathway, not a shortcut or generic route, and that RLEs fill a genuine terminology gap. The goal is clarity, not reclassification, and the practical outcome is greater access and supply stability for patients with neuroendocrine tumors.